Prelude Therapeutics Inc
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a precision oncology company that discovers and develops targeted cancer medicines for patients with underserved cancers and limited treatment options. Its pipeline includes small-molecule inhibitors, targeted protein degraders and precision antibody-drug conjugates;… From the company’s description.
In fiscal 2025, Prelude Therapeutics Inc reported revenue of $12.14M, up 73.4% from fiscal 2024, and a net loss of $99.50M. Its operating margin was −861.3%, and operations used $56.30M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Prelude Therapeutics Inc does
In the company’s own words
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a precision oncology company that discovers and develops targeted cancer medicines for patients with underserved cancers and limited treatment options. Its pipeline includes small-molecule inhibitors, targeted protein degraders and precision antibody-drug conjugates; lead programs include a mutant-selective JAK2 V617F inhibitor and a KAT6A-selective degrader, alongside preclinical programs targeting mutated calreticulin and other cancer pathways. The company also collaborates with AbCellera on degrader antibody conjugates, combining its degrader expertise with the partner’s antibody capabilities. Prelude has one operating business focused on oncology drug discovery and development, with programs at preclinical and clinical stages rather than commercial products. It has advanced multiple programs into clinical trials since its founding in 2016, while prioritizing JAK2 V617F and KAT6A after pausing clinical development of its SMARCA2 degrader program in 2025. Its website is https://www.preludetx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 1678660
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Prelude Therapeutics Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Prelude Therapeutics Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Prelude Therapeutics Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Prelude Therapeutics Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Prelude Therapeutics Inc's last four quarterly filings that the numbers alone won't show?”